MDXG

Hulse William Frank IV

Known title: General CounselCIK: 0001796044

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.

this person other insiders at MDXG

Transaction History

MDXG▼ Sell$89K
MDXG▲ Buy$614K
MDXG▼ Sell$277K
MDXG▲ Buy$0
MDXG▼ Sell$66K
MDXG▼ Sell$60K
MDXG▼ Sell$61K
MDXG▼ Sell$270K
MDXG▼ Sell$161K
MDXG▼ Sell$635K
MDXG▲ Buy$0
MDXG▲ Buy$0
MDXG▼ Sell$64K
MDXG▼ Sell$58K
MDXG▼ Sell$61K
MDXG▼ Sell$162K
MDXG▼ Sell$127K
MDXG▲ Buy$0
MDXG▼ Sell$35K
MDXG▼ Sell$22K
MDXG▼ Sell$20K
MDXG▲ Buy$630K
MDXG▼ Sell$48K
MDXG▼ Sell$70K
MDXG▲ Buy$825K
MDXG▼ Sell$49K
MDXG▼ Sell$60K

We use analytics to understand how market-wall is used. No personal data is sold.